Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer ...Middle East

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...

Hence then, the article about innovent delivers oral presentations at the 2024 asco annual meeting on clinical data of first in class anti cldn18 2 cd3 bispecific antibody ibi389 for the treatment of advanced pancreatic cancer and gastric cancer was published today ( Monday 03/06/2024 - 04:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• 2 found dead after family disturbance reported in Concord
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor